Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.45 |
| ▸ | PPARG | P37231 | 5/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6818300 | 0.83 | FFAR1 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6821601 | 0.82 | PPARG (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6813954 | 0.80 | PPARG (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7247920 | 0.74 | PPARG (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5992721 | 0.73 | PPARA (0.79) | PPARGPPARA | |
| SCHEMBL5991859 | 0.73 | PPARA (0.79) | PPARGPPARA | |
| SCHEMBL4029473 | 0.72 | PPARG (0.65) | PPARGPPARA | |
| SCHEMBL6818759 | 0.70 | PPARG (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7243191 | 0.70 | PPARG (0.52) | FFAR1PPARGPPARA | |
| SCHEMBL5994705 | 0.70 | PPARA (0.64) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237857-B1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | ASTRAZENECA AB (SE) | 2004-06-30 | — | — | EP | disclosed |
| US-6630509-B2 | Pharmaceutical medication associated with insulin resistance; patient with prophylaxis conditions having reduced sensitivity to insulin | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | disclosed |
| US-20030018207-A1 | Phenalkyloxy-phenyl derivatives | ASTRAZENECA AB (SE) | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018207-A1 | Phenalkyloxy-phenyl derivatives | GPR119, INSR, IAPP | CA12 4857/4885CA1 4884/4885CA2 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.